glp-1 receptor agonists effects on cardiovascular risk reduction Impact of outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis | Clinical Research in Cardiology GLP-1 receptor agonists and cardiovascular

5) Adjust meals to support the gut Very small meals can reduce stool volume

Prespecified and post hoc analyses confirmed the consistent effects of dapagliflozin across kidney disease: improving global outcomes (KDIGO) risk categories [56,57]

Flexible dose adjustment of oral semaglutide led to superior glycemic control and weight loss at week 52 versus sitagliptin and was well tolerated

Motor performance and functionality improvements were seen, with a lower disability score observed in the intranasal insulin group compared to baseline scores, suggesting that intranasal insulin may be a feasible treatment for PD

GLP-1RAs, specifically liraglutide, have also been evaluated for their effects on cardiovascular biomarkers

doi: 10.3390/antiox11112296 59 WangFSWangWGuSMQiDSmithNAPengWGet al